Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

Badstick Mar. 16 at 1:50 AM

$PSTV May to the finish line….

0 · Reply

bmoney83 Mar. 15 at 9:47 PM

$PSTV

0 · Reply

Old_Bag Mar. 15 at 9:46 PM

$PSTV Worthless

0 · Reply

Bazzzigar Mar. 15 at 8:02 PM

$PSTV JUNK

0 · Reply

Investor1862 Mar. 15 at 5:00 PM

$PSTV crap.

0 · Reply

Love_To_Learn Mar. 14 at 2:20 PM

$PSTV WILL CHANGE OUR TEMP LIQUIDITY VACUUM AND WITH VOLUME WELL OVER 8.27 MILLION * CODING AND DONE !

0 · Reply

Love_To_Learn Mar. 14 at 2:18 PM

$PSTV CHANGING FROM ALTERNATIVE THERAPY TO AN INTEGRATED 1. ONCE WE FUSE BACK WITH NANO PARTICLE WILL USE U TO APPLY THIS ACROSS THE ENTIRE MARKET ACCORDINGLY

2 · Reply

Love_To_Learn Mar. 14 at 2:18 PM

$PSTV MERGING CODES TO NOT FORCE HOSPITALS BILLING SYSTEMS AND PROTOCOL FOR PAYMENT AND PAYOUT 77412 infrastructure

0 · Reply

Love_To_Learn Mar. 14 at 2:14 PM

$PSTV DELEVERAGING YOUR DRUG FOCUS ENTIRELY

1 · Reply

Love_To_Learn Mar. 14 at 2:14 PM

$PSTV ATTACHING FEW NEW Z-CODES TO U MULTIPLE DEX Z CODE AS 1 CHANGING YOUR SCIENCE PROJECT TO INFRASTRUCTURE PROVIDER

0 · Reply

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Feb 25, 2026, 7:30 AM EST - 18 days ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

Jan 22, 2026, 11:34 AM EST - 7 weeks ago

Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript

Jan 21, 2026, 4:15 PM EST - 7 weeks ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 11:36 AM EST - 2 months ago

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Jan 14, 2026, 8:00 AM EST - 2 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 8, 2026, 7:30 AM EST - 2 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 11 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 7:42 PM EDT - 1 year ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Badstick Mar. 16 at 1:50 AM

$PSTV May to the finish line….

0 · Reply

bmoney83 Mar. 15 at 9:47 PM

$PSTV

0 · Reply

Old_Bag Mar. 15 at 9:46 PM

$PSTV Worthless

0 · Reply

Bazzzigar Mar. 15 at 8:02 PM

$PSTV JUNK

0 · Reply

Investor1862 Mar. 15 at 5:00 PM

$PSTV crap.

0 · Reply

Love_To_Learn Mar. 14 at 2:20 PM

$PSTV WILL CHANGE OUR TEMP LIQUIDITY VACUUM AND WITH VOLUME WELL OVER 8.27 MILLION * CODING AND DONE !

0 · Reply

Love_To_Learn Mar. 14 at 2:18 PM

$PSTV CHANGING FROM ALTERNATIVE THERAPY TO AN INTEGRATED 1. ONCE WE FUSE BACK WITH NANO PARTICLE WILL USE U TO APPLY THIS ACROSS THE ENTIRE MARKET ACCORDINGLY

2 · Reply

Love_To_Learn Mar. 14 at 2:18 PM

$PSTV MERGING CODES TO NOT FORCE HOSPITALS BILLING SYSTEMS AND PROTOCOL FOR PAYMENT AND PAYOUT 77412 infrastructure

0 · Reply

Love_To_Learn Mar. 14 at 2:14 PM

$PSTV DELEVERAGING YOUR DRUG FOCUS ENTIRELY

1 · Reply

Love_To_Learn Mar. 14 at 2:14 PM

$PSTV ATTACHING FEW NEW Z-CODES TO U MULTIPLE DEX Z CODE AS 1 CHANGING YOUR SCIENCE PROJECT TO INFRASTRUCTURE PROVIDER

0 · Reply

Love_To_Learn Mar. 14 at 2:08 PM

$PSTV PLACED TRACES OF NANO PARTICLE ON 0.34* WE WILL REFUSE WITH NANO PARTICLE 0.34* 4 NEXT STAGES OF NANO PARTICLE AND GLOBAL DYNAMICS ALSO LINKED TO ISRAEL

0 · Reply

Love_To_Learn Mar. 14 at 2:07 PM

$PSTV MAKING A CHANGE TO YOUR 0.34*

0 · Reply

Love_To_Learn Mar. 14 at 1:59 PM

$PSTV Z-CODE ACCESS GRANTED APPLYING NEW Z-CODES *

0 · Reply

Dummass Mar. 14 at 1:58 PM

$PSTV Total dud. Dilution is paying CEO over 1.3 mill a year. Criminal.

1 · Reply

Love_To_Learn Mar. 14 at 1:58 PM

CHANGING OVERHEAD SUPPLY FOR MANY STOCKS ACROSS THE WHOLE MARKET U R ONE OF THEM $PSTV

0 · Reply

bmoney83 Mar. 14 at 1:58 PM

$PSTV

0 · Reply

Hoekie12 Mar. 14 at 10:36 AM

$PSTV With reasons 🙄 https://stocktwits.com/AliceNChains/message/647527160

0 · Reply

Badstick Mar. 14 at 2:00 AM

$PSTV

0 · Reply

Badstick Mar. 14 at 1:59 AM

$PSTV Love it!

0 · Reply

AliceNChains Mar. 14 at 12:58 AM

$PSTV I see Mo is back with his alter ego to decipher and promote himself again. You would think this Mo joker has almighty power over the market.

0 · Reply

Vulnerable Mar. 14 at 12:46 AM

$PSTV I'm more familiar the Mo curse of imminent (adds up to 13) but soon and quickly ring to the same too - bad news for longs, good news for shorts. I at 13 Japanese sweet potatoes last night. coincidence, i think not. Could R/S be 23 to 1 or 13 to one? think larger, 338/1 (13*23).

0 · Reply

AliceNChains Mar. 13 at 11:27 PM

$PSTV 74.5% short ratio today and you wonder why it went down. The short conspiracy collaborators worked together hard today to spread those nano particles. 45 trillion off the books but intact 😂😂😂

0 · Reply

Market Cap	34.73M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.02%
Debt to Equity Ratio	0.00

Volume	8,265,900
Avg Vol	10,873,782
Day's Range	N/A - N/A
Shares Out	138.90M
Stochastic %K	8%
Beta	0.79
Analysts	Strong Sell
Price Target	$6.38